GPCR Structure Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1888886 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-39.5%
TTM EPS YoY-6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.5%
ROA-27.1%
ROIC (approx.)-32.3%
Asset turnover—
Leverage & solvency
Liabilities / assets8.4%
Debt / equity0.00x
Current ratio11.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $225.25M | $108.81M |
| SG&A expense | $61.55M | $49.41M |
| Operating income | -$176.56M | -$158.23M |
| Pretax income | -$140.69M | -$122.22M |
| Income tax | $515,000 | $310,000 |
| Net income | -$141.20M | -$122.53M |
| EBITDA | -$175.23M | -$157.24M |
| EPS (basic) | -0.80 | -0.78 |
| EPS (diluted) | -0.80 | -0.78 |
| Weighted avg. shares (diluted) | 177.60M | 157.92M |
| Balance sheet | ||
| Cash & equivalents | $799.62M | $169.51M |
| Short-term investments | $646.57M | $714.01M |
| Current assets | $1.57B | $891.21M |
| PP&E, net | $6.65M | $3.48M |
| Total assets | $1.58B | $903.33M |
| Current liabilities | $63.28M | $36.02M |
| Total liabilities | $67.54M | $38.49M |
| Shareholders' equity | $1.52B | $864.84M |
| Shares outstanding | 212.51M | 171.86M |
| Cash flow statement | ||
| Operating cash flow | -$222.20M | -$116.64M |
| Capital expenditure | $3.61M | $1.29M |
| Free cash flow | -$225.81M | -$117.93M |
| Investing cash flow | $89.80M | -$358.91M |
| Financing cash flow | $762.52M | $515.26M |
| Depreciation & amortization | $1.33M | $992,000 |
| Stock-based compensation | $28.99M | $18.79M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.